FWBI RSI Chart
Last 7 days
9.6%
Last 30 days
-16.7%
Last 90 days
-47.5%
Trailing 12 Months
-0.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | romano sarah | sold | -317 | 4.2294 | -75.00 | chief financial officer |
Apr 01, 2024 | sapirstein james | sold | -735 | 4.2294 | -174 | chairman and ceo |
Mar 15, 2024 | romano sarah | sold | -5,555 | 4.96 | -1,120 | chief financial officer |
Mar 15, 2024 | sapirstein james | sold | -9,359 | 4.96 | -1,887 | chairman and ceo |
Mar 13, 2024 | syage jack | acquired | - | - | 15,400 | president & coo |
Mar 13, 2024 | khosla chaitan phd | acquired | - | - | 440 | - |
Jan 12, 2024 | romano sarah | sold | -411 | 4.2 | -98.00 | chief financial officer |
Jan 12, 2024 | sapirstein james | sold | -697 | 4.2 | -166 | chairman, president and ceo |
Jan 02, 2024 | coelho mary theresa | acquired | - | - | 19,633 | - |
Jan 02, 2024 | riddell alastair | acquired | - | - | 19,633 | - |
Which funds bought or sold FWBI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -15.62 | -1,430 | 10,481 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | new | - | 118,260 | 118,260 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | new | - | 48,269 | 48,269 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -6,455 | - | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 116 | 32.00 | 57.00 | -% |
May 08, 2024 | US BANCORP \DE\ | unchanged | - | - | 4.00 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 17, 2024 | Kathleen S. Wright Associates Inc. | unchanged | - | - | 4.00 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -15,000 | - | -% |
Unveiling First Wave BioPharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
First Wave BioPharma, Inc. News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 1224.0% | 91,134 | 6,883 | 5,927 | 4,328 | 5,534 | 5,440 | 4,645 | 3,927 | 8,825 | 11,790 | 12,424 | 13,777 | 17,983 | 12,924 | 16,722 | 6,862 | 8,184 | 8,903 | 9,436 | 9,612 | 8,957 |
Current Assets | 51.1% | 7,490 | 4,956 | 3,977 | 2,354 | 3,530 | 3,413 | 2,549 | 1,789 | 6,550 | 9,425 | 7,502 | 8,615 | 13,170 | 7,870 | 11,538 | 1,601 | 2,897 | 3,408 | 3,730 | 3,629 | 2,804 |
Cash Equivalents | -7.5% | 3,432 | 3,712 | 3,300 | 1,200 | 2,064 | 1,363 | 1,700 | 1,155 | 5,695 | 8,249 | 7,200 | 8,074 | 12,026 | 6,062 | 11,369 | 985 | 1,630 | 176 | 1,550 | 1,311 | 414 |
Net PPE | 76.8% | 26.00 | 15.00 | 22.00 | 29.00 | 37.00 | 44.00 | 51.00 | 58.00 | 66.00 | 73.00 | 80.00 | 89.00 | 92* | 18.00 | 54.00 | 62.00 | 74.00 | 77.00 | 95.00 | 108 | 125 |
Goodwill | 1089.8% | 20,039 | 1,684 | 1,684 | 1,684 | 1,684 | 1,684 | 1,715 | 1,756 | 1,862 | 1,912 | 1,945 | 1,991 | 1,974 | 2,054 | 1,969 | 1,890 | 1,844 | 1,887 | 1,833 | 1,914 | 1,887 |
Liabilities | 304.5% | 13,270 | 3,280 | 2,648 | 3,446 | 2,821 | 2,698 | 6,925 | 18,117 | 18,065 | 19,612 | 19,394 | 6,740 | 3,581 | 15,565 | 2,657 | 7,659 | 5,143 | 4,286 | 6,234 | 6,664 | 6,243 |
Current Liabilities | 97.0% | 6,173 | 3,133 | 2,482 | 3,261 | 2,625 | 2,483 | 6,694 | 17,284 | 14,216 | 12,300 | 19,098 | 6,454 | 3,575 | 15,545 | 2,625 | 7,616 | 5,143 | 4,286 | 5,819 | 6,221 | 5,757 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5,285 | 2,986 | 1,077 | 1,947 | 1,837 | 1,728 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,077 | - | - | - |
Shareholder's Equity | 349.2% | 16,183 | 3,603 | 3,279 | 882 | 2,713 | 2,742 | - | - | - | -7,821 | 6,970 | 7,037 | 14,402 | - | 14,065 | - | 3,041 | 4,617 | 3,202 | 2,948 | 2,713 |
Retained Earnings | 3.0% | -178,800 | -184,328 | -180,200 | -176,800 | -172,600 | -168,533 | -164,547 | -168,939 | -163,500 | -153,904 | -142,731 | -112,330 | -103,051 | -95,366 | -77,965 | -72,651 | -67,956 | -62,694 | -61,413 | -57,220 | -52,177 |
Additional Paid-In Capital | 3.7% | 194,944 | 187,931 | 183,505 | 177,675 | 175,317 | 171,276 | 163,722 | 156,166 | 155,571 | 147,307 | 137,028 | 120,585 | 118,693 | 93,838 | 93,240 | 73,124 | 72,103 | 68,576 | 65,969 | 61,386 | 56,135 |
Shares Outstanding | 29.7% | 2,025 | 1,561 | 673 | 210 | 77.00 | 50.00 | 11.00 | 4.00 | 4.00 | 4.00 | 2.00 | 2.00 | 1.00 | 741.67* | - | - | - | - | - | - | - |
Float | - | - | - | - | 6,700 | - | - | - | 4,500 | - | - | - | 67,100 | - | - | - | 25,200 | - | - | - | 31,400 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -8.9% | -3,746 | -3,439 | -3,331 | -2,761 | -2,845 | -5,592 | -4,254 | -4,585 | -7,912 | -5,862 | -15,729 | -5,622 | -5,073 | -5,889 | -2,696 | -1,343 | -1,291 | -3,225 | -4,153 | -4,025 | -2,627 |
Share Based Compensation | 115.2% | 271 | 126 | 263 | 293 | 358 | 84.00 | 92.00 | 375 | 218 | 102 | 182 | 314 | 772 | 153 | 128 | 177 | 55.00 | 33.00 | 30.00 | - | 511 |
Cashflow From Investing | - | 88.00 | - | - | - | - | - | - | - | - | -10,248 | 2.00 | -73.93 | - | 90.00 | - | 2.00 | -4.34 | -6.85 | -3.91 | 15* | -13.35 |
Cashflow From Financing | -22.5% | 3,379 | 4,359 | 5,387 | 1,933 | 3,547 | 5,524 | 4,772 | 76.00 | 5,367 | 17,073 | 14,858 | 1,782 | 11,051 | 552 | 13,060 | 677 | 2,756 | 1,846 | 4,403 | 4,928 | 1,967 |
Condensed Consolidated Statements of Operations (unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development expenses | $ 565,962 | $ 1,361,683 |
General and administrative expenses | 8,659,692 | 2,700,742 |
Total operating expenses | 9,225,654 | 4,062,425 |
Loss from operations | (9,225,654) | (4,062,425) |
Other (expenses) income: | ||
Interest expense | (66,202) | (8,987) |
Interest income | 228 | 1,873 |
Other expense | (653) | (1,114) |
Total other expenses | (66,627) | (8,228) |
Loss before income tax benefit | (9,292,281) | (4,070,653) |
Income tax benefit | 14,859,887 | |
Net income (loss) | 5,567,606 | (4,070,653) |
Preferred stock dividends | (66,144) | (87,431) |
Net income (loss) applicable to common shareholders | $ 5,501,462 | $ (4,158,084) |
Basic weighted average shares outstanding | 1,761,953 | 114,033 |
Diluted weighted average shares outstanding | 14,511,461 | 114,033 |
Income (loss) per share - basic | $ 3.12 | $ (36.46) |
Income (loss) per share - diluted | $ 0.38 | $ (36.46) |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 3,431,913 | $ 3,711,770 |
Prepaid expenses | 4,058,053 | 1,244,466 |
Total Current Assets | 7,489,966 | 4,956,236 |
Property, equipment, and leasehold improvements, net | 25,749 | 14,565 |
Other Assets: | ||
Restricted cash | 21,522 | 21,522 |
Patents and tradenames | 365,486 | |
In - process R&D | 63,000,000 | |
Goodwill | 20,038,508 | 1,684,182 |
Operating lease right-of-use assets | 181,421 | 195,440 |
Deposits | 11,250 | 11,250 |
Total Other Assets | 83,618,187 | 1,912,394 |
Total Assets | 91,133,902 | 6,883,195 |
Current Liabilities: | ||
Accounts payable | 1,996,519 | 554,277 |
Accrued expenses | 2,554,446 | 825,290 |
Accrued dividend payable | 1,135,760 | 1,069,616 |
Note payable | 386,769 | 612,784 |
Operating lease liabilities | 71,216 | 67,111 |
Other current liabilities | 28,546 | 4,239 |
Total Current Liabilities | 6,173,256 | 3,133,317 |
Long - term debt | 6,397,889 | |
Deferred tax liability | 571,221 | |
Non-current operating lease liabilities | 127,592 | 146,949 |
Total Liabilities | 13,269,958 | 3,280,266 |
Mezzanine Equity: | ||
Total Mezzanine Equity | 61,681,100 | |
Stockholders' Equity: | ||
Common stock - Par value $0.0001 per share; 100,000,000 shares authorized; 2,025,208 and 1,560,998 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 203 | 156 |
Additional paid-in capital | 194,943,707 | 187,931,445 |
Accumulated deficit | (178,761,066) | (184,328,672) |
Total Stockholders' Equity | 16,182,844 | 3,602,929 |
Total Liabilities, Mezzanine Equity and Stockholders' Equity | 91,133,902 | 6,883,195 |
Series B Preferred Stock | ||
Stockholders' Equity: | ||
Preferred stock | 0 | 0 |
Series C Preferred Stock | ||
Stockholders' Equity: | ||
Preferred stock | 0 | 0 |
Series D Preferred Stock | ||
Stockholders' Equity: | ||
Preferred stock | 0 | 0 |
Series E Preferred Stock | ||
Stockholders' Equity: | ||
Preferred stock | 0 | 0 |
Series F Preferred Stock | ||
Stockholders' Equity: | ||
Preferred stock | 0 | $ 0 |
Series G Preferred Stock | ||
Mezzanine Equity: | ||
Total Mezzanine Equity | $ 61,681,100 |